THE WOODLANDS, Texas, June 22, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announced today the Company will conduct clinical evaluations on its early detection breast cancer NAF Test (nipple aspirate fluid) this summer. The Company's NAF Test, for the detection, diagnosis, and monitoring of breast cancer, utilizes fluids from the breast called nipple aspirates to identify groups of breast cancer proteins. Through proteomic analysis of this breast ductal fluid, the Company believes it has engineered the first test of its type that detects breast cancer years earlier than current technology.
The collection of the nipple aspirate fluid, obtained from the regions of the breast where most breast cancers originate, is a non-invasive procedure utilizing a modified breast pump to obtain a drop of fluid from the nipple. The aspirate is analyzed to identify the specific breast cancer protein footprints. This breakthrough technology resulted from the joint development efforts of the Company and M.D. Anderson Cancer Center.
The Company has completed the initial proof-of-concept with notable effectiveness and is currently prepared to move forward with validation and product rollout. The Company has recently secured the intellectual property for the NAF Test and continues to expand its intellectual property and biomarker portfolio.
Ira L. Goldknopf, Ph.D., Chief Scientific Officer of Power3 Medical commented, "This technology holds great promise for commercialization in large and growing markets as it provides a mechanism to achieve earlier and more accurate indications of breast cancer as well as to identify specific drug targets for earlier treatment of cancer. The fluids are obtained non-invasively with the proteins in the fluid revealing specific 'disease protein footprints' when analyzed by our patented technology. The initial clinical evaluation of this product proved remarkably effective and we are extremely excited to begin our summer clinical trials."
About Power 3 Medical Products, Inc.
Power 3 Medical Products, www.power3medical.com, is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company is in a strong competitive position with over 250 identified biomarkers of human disease and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
In addition, all current shareholders, and interested parties should sign into our private Corporate Guest Book, www.CorporateGuestBook.com/?PWRM to receive timely updates and information on future developments.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.